Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC.
The treatment of hemophilia A patients has progressed in the last 30 years. The development of more pure factor VIII concentrates has been encouraged by the appearance of the human immunodeficiency virus in blood supply. Monoclate was the first essentially pure form of factor VIII available for hemophilia therapy. The liquid pasteurized form of Monoclate represents a new standard for therapy that attempts to eliminate a broad spectrum of viral content in factor VIII preparations.
Hrinda
M E
ME
Biotechnology Department, Rorer Central Research, King of Prussia, PA 19406.
Feldman
F
F
Schreiber
A B
AB
D000911:Antibodies, Monoclonal; D015153:Blotting, Western; D004340:Drug Contamination; D005169:Factor VIII / Q000032:analysis* / Q000302:isolation & purification; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D013242:Sterilization; D014780:Viruses; D014841:von Willebrand Factor / Q000276:immunology
D000911:Antibodies, Monoclonal; D014841:von Willebrand Factor; D005169:Factor VIII